Dr Suceena Alexander is currently the Professor in the Department of Nephrology and Head of Nephrology Unit III, Christian Medical College, Vellore, India. She is also the faculty-in-charge of the Nephrology Lab in her department. Her other academic positions include Former Addl. Vice Principal (Research), Senior Fellow (Clinical and Public Health), DBT/ Wellcome Trust India Alliance (2023-2028), Member, South Asia Regional Board, International Society of Nephrology and Associate Editor, Indian Journal of Nephrology. She is also the Member Secretary for institutional ethics committee. She was awarded the Early Career Fellowship (Clinical and Public Health), by DBT/ Wellcome Trust India Alliance (2015-2022) for project titled ‘“Why is IgA nephropathy aggressive in Indians”. She has recently been awarded the Senior Fellowship (Clinical and Public Health), by DBT/ Wellcome Trust India Alliance (2023-2028) for project titled “Randomized Embedded Adaptive Platform Clinical Trial in South Asian Kidney Biopsy-Proven Primary Glomerular Diseases: Multi-center, Multi-arm and Multi-stage”. She is also the PI for project titled “Diagnostic utility and clinical impact of genomic testing in adolescent and adult kidney disease patients with suspected monogenic etiology by establishing an integrated multi-institutional Kidney Genetics Service- a pragmatic prospective observational cohort study funded by ICMR (2023-2026). She supervises nephrology residents and MSc/ PhD scholars regularly. Her research interests include glomerular diseases, renal genetics, renal regenerative medicine, and ethnic differences in kidney diseases. She has authored book chapters and more than 50 peer reviewed publications.
Publications
1. Barratt J, Barbour SJ, Brenner RM, Cooper K, Wei X, Eren N, Floege J, Jha V, Kim SG, Maes B, Phoon RKS, Singh H, Tesař V, Lafayette R; ORIGIN Phase 2b Investigators. Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA Nephropathy. J Am Soc Nephrol. 2025 Apr 1;36(4):679-687. doi: 10.1681/ASN.0000000541. Epub 2024 Oct 26. PMID: 39462308; PMCID: PMC7616790.
2. Cheung CK, Alexander S, Reich HN, Selvaskandan H, Zhang H, Barratt J. The pathogenesis of IgA nephropathy and implications for treatment. Nat Rev Nephrol. 2025 Jan;21(1):9-23. doi: 10.1038/s41581-024-00885-3. Epub 2024 Sep 4. PMID: 39232245; PMCID: PMC7616674.
3. Mathur M, Barratt J, Chacko B, Chan TM, Kooienga L, Oh KH, Sahay M, Suzuki Y, Wong MG, Yarbrough J, Xia J, Pereira BJG; ENVISION Trial Investigators Group. A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy. N Engl J Med. 2024 Jan 4;390(1):20-31. doi: 10.1056/NEJMoa2305635. Epub 2023 Nov 2. PMID: 37916620; PMCID: PMC7615905.
4. John EE, Thomas A, Eapen JJ, Yusuf S, Roy S, Valson AT, David VG, Varughese S, Alexander S. Latency, Anti-Bacterial Resistance Pattern, and Bacterial Infection-Related Glomerulonephritis. Clin J Am Soc Nephrol. 2021 Aug;16(8):1210-1220. doi: 10.2215/CJN.18631120. Epub 2021 Jun 7. PMID: 34099500; PMCID: PMC8455032.
5. Alexander S, Varughese S, Franklin R, Rebekah G, Roy S, Yusuf S, Thomas A, Eapen JJ, John EE, Valson AT, David VG, Daha MR, Feehally J, Barratt J, John GT. Three-Year Clinical Outcomes of the First South Asian Prospective Longitudinal Observational IgA Nephropathy Cohort. Kidney Int Rep. 2021 Nov 24;7(2):305-318. doi: 10.1016/j.ekir.2021.11.012. PMID: 35155869; PMCID: PMC8820995.
